TW201607531A - 癌幹細胞之增殖抑制劑 - Google Patents
癌幹細胞之增殖抑制劑 Download PDFInfo
- Publication number
- TW201607531A TW201607531A TW104116251A TW104116251A TW201607531A TW 201607531 A TW201607531 A TW 201607531A TW 104116251 A TW104116251 A TW 104116251A TW 104116251 A TW104116251 A TW 104116251A TW 201607531 A TW201607531 A TW 201607531A
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer stem
- cancer
- stem cells
- cells
- proliferation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 125
- 201000011510 cancer Diseases 0.000 title claims abstract description 97
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 90
- 239000003112 inhibitor Substances 0.000 title claims abstract description 36
- 230000004663 cell proliferation Effects 0.000 title abstract description 12
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 claims abstract description 104
- 230000035755 proliferation Effects 0.000 claims abstract description 65
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 45
- 150000004492 retinoid derivatives Chemical class 0.000 claims abstract description 34
- 239000000556 agonist Substances 0.000 claims abstract description 32
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 230000001973 epigenetic effect Effects 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 230000010721 Tubulin Interactions Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 121
- 229950010130 tamibarotene Drugs 0.000 abstract description 99
- 230000000694 effects Effects 0.000 abstract description 59
- 230000005764 inhibitory process Effects 0.000 abstract description 24
- 238000000034 method Methods 0.000 abstract description 9
- 230000006907 apoptotic process Effects 0.000 abstract description 5
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 abstract description 4
- 229960002938 bexarotene Drugs 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 59
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 59
- 201000002528 pancreatic cancer Diseases 0.000 description 59
- 208000008443 pancreatic carcinoma Diseases 0.000 description 59
- 241000699670 Mus sp. Species 0.000 description 20
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 19
- 229960002756 azacitidine Drugs 0.000 description 19
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 14
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 14
- 229960000604 valproic acid Drugs 0.000 description 14
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 13
- 229960003668 docetaxel Drugs 0.000 description 13
- 239000002771 cell marker Substances 0.000 description 12
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 11
- 229960005277 gemcitabine Drugs 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 230000002301 combined effect Effects 0.000 description 7
- 238000004114 suspension culture Methods 0.000 description 7
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 6
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 6
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 238000011278 co-treatment Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 6
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 102100032912 CD44 antigen Human genes 0.000 description 4
- 230000007067 DNA methylation Effects 0.000 description 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 4
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 4
- 102100038081 Signal transducer CD24 Human genes 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 230000002900 effect on cell Effects 0.000 description 3
- 230000009982 effect on human Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
- 229960002411 imatinib Drugs 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 229960004671 enzalutamide Drugs 0.000 description 2
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 229940099419 targretin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 241000001488 Bothrioplana sinensis Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229940122429 Tubulin inhibitor Drugs 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000000603 stem cell niche Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Epoxy Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本發明課題為提供一種增殖抑制劑,其係抑制現存抗癌劑治療法中表現出抵抗性的癌幹細胞之增殖,透過細胞凋亡來發揮作用。
本發明為一種癌幹細胞之增殖抑制劑,其係以類視色素促效劑(宜為他米巴羅汀)單劑或其與類視色素合成物促效劑(宜為蓓薩羅丁)兩劑作為有效成分之癌幹細胞之增殖抑制劑,而且藉由併用各種抗癌劑來增強抗癌劑的效果。
Description
本發明關於一種癌幹細胞之增殖抑制劑,詳細而言關於一種在現存抗癌劑治療法中表現出抵抗性的癌幹細胞之增殖抑制劑。
醫學的發展之中,癌症治療是進步極快的領域,其治療法種類繁多。儘管如此,在日本厚生勞働省的人口動態調查或世界保健機構的調查中,預測癌症死亡人數今後還會增加。其中一個原因是在現存的抗癌劑治療中表現出抵抗性的癌幹細胞的存在,而正受到矚目。
癌細胞會因為遺傳變異的累積或癌細胞周圍的微小環境變化等變得具有高增殖能力、浸潤能力、轉移能力,然而並不是構成癌塊的癌細胞的全部都兼具這些特徵。近年來解明了具有這些特徵,使癌症發生並且惡化能力高的細胞,只佔了全體的極小部分(非專利文獻1)。具有這種特徵的癌細胞,也具有自行複製能力與可分化成多種細胞的多分化能力這兩個可在幹細胞共通觀察到的特徵,因此被稱為癌幹細胞。目前為止,在急性白血病、乳
癌、大腸癌、腦腫瘤、前列腺癌、胰臟癌等的癌種之中,可觀察到其存在。
另外,近年來逐漸發現癌幹細胞在現存抗癌劑治療法中會表現出抵抗性。例如在急性白血病的情況,癌幹細胞會留在被稱為幹細胞壁龕的微小環境,而進入細胞分裂休止的休眠期(G0期),此狀態下,會對於抗癌劑的治療產生抗性。另外,許多固態癌的幹細胞的P糖蛋白等的表現高,會對抗癌劑表現出抗性。此外還判明了抗癌劑治療後的癌組織中,癌幹細胞存在比率比治療前還高。
這些現象被認為是抗癌劑治療後無法根治癌症而復發的一大原因,逐漸發現以癌幹細胞為標靶的治療劑的開發是根治癌症的重要方法。目前為止已有文獻報告出以癌幹細胞為標靶的治療劑可抑制癌的增殖,增強現存抗癌劑的治療效果。然而,目前臨床現場並未建立以癌幹細胞為標靶的治療劑,現況中希望開發出這種藥劑(非專利文獻2)。於是,本發明人等為了開發出使用癌幹細胞標記,可臨床應用,並以癌幹細胞為標靶的新治療劑,而進行了檢討(非專利文獻3)。
非專利文獻1:Proc. Natl. Acad. Sci. USA 100, 3983-3988(2003)
非專利文獻2:Nature 453, 338-344(2008)
非專利文獻3:Mol. Cancer Res. 7, 330-338(2009)
然而非常希望有一種癌幹細胞之增殖抑制劑,能夠更有效抑制在現存的抗癌劑治療法中表現出抵抗性的癌幹細胞之增殖。
於是,本發明的目在於提供一種癌幹細胞之增殖抑制劑,可有效抑制對於現存的抗癌劑治療法表現出抵抗性的癌幹細胞的增殖。
本發明人等為了解決上述課題,著眼於癌幹細胞內資訊傳達路徑而鑽研檢討。
亦即,癌幹細胞會藉由許多細胞內資訊傳達路徑而維持未分化狀態,而具有維持癌的能力。阻礙這些資訊傳達路徑的物質,可藉由誘導癌幹細胞的分化或細胞凋亡來抑制癌的增殖,被認為是新抗癌劑的目標。
於是本發明人等,使用類視色素(retinoid)及類視色素合成物(rexinoid),在檢討類視色素及類視色素合成物所發揮的增殖、生存、分化、細胞凋亡等的生理學作用,包括使癌幹細胞分化、細胞凋亡等的增殖抑制作用時,認為可成為新的抗癌劑。
在檢討癌幹細胞的增殖抑制作用時,由於癌
幹細胞是癌細胞中一部分的集團,因此決定以癌幹細胞標記作為指標來進行檢討,人類胰臟癌細胞會表現出各種癌幹細胞標記,故使用此細胞進行檢討。
結果發現,藉由單獨使用類視色素促效劑,尤其是他米巴羅汀(Am-80)、或與類視色素合成物促效劑併用,尤其是蓓薩羅丁,可抑制人類胰臟癌細胞的細胞數量、形態、幹細胞標記的表現。另外,類視色素受體(RAR)及類視色素合成物受體(RXR)是核內轉錄因子的其中一個,考慮到與抑制表觀遺傳作用的化合物或藥劑的交互作用,因此與含有這些抑制化合物或作用機制相異的分子標的藥之抗癌劑併用,結果發現顯著表現出癌幹細胞的增殖抑制作用。本發明基於這樣的見解而完成。
亦即,本發明關於下述(1)~(7)。
(1)一種癌幹細胞之增殖抑制劑,其係以類視色素促效劑作為有效成分。
(2)如前述(1)所記載之癌幹細胞之增殖抑制劑,其中前述類視色素促效劑為他米巴羅汀(Am-80)。
(3)如前述(1)或(2)所記載之癌幹細胞之增殖抑制劑,其中進一步以類視色素合成物促效劑作為有效成分。
(4)如前述(3)所記載之癌幹細胞之增殖抑制劑,其中前述類視色素合成物促效劑為蓓薩羅丁。
(5)如前述(1)~(4)中任一項之癌幹細胞之增殖抑制劑,其中含有抗癌劑。
(6)如前述(5)所記載之癌幹細胞之增殖抑制劑,其中含有類視色素促效劑0.5~20mg/人類個體,含有類視色素促效劑與類視色素合成物促效劑合計0.5~500mg/人類個體,且含有抗癌劑1.0~1000mg/人類個體。
(7)如前述(5)或(6)所記載之癌幹細胞之增殖抑制劑,其中前述抗癌劑係選自DNA交互作用劑、代謝拮抗劑、微管蛋白交互作用劑、分子標的治療劑、表觀遺傳之作用阻礙劑及荷爾蒙劑所構成之群。
依據本發明,藉由單獨投予類視色素促效劑、或與類視色素合成物促效劑合併投予,可減少癌幹細胞。另外,進一步藉由投予抗癌劑,可減少或縮小腫瘤塊的體積。另外,同時投予類視色素促效劑及類視色素合成物促效劑與抗癌劑的方法也有用。依據本發明,可治療的癌症例如有在抗癌劑治療中表現出抵抗性的急性骨髓性白血病、非何杰金氏淋巴腫等的血液癌、胰臟癌、肝細胞癌、大腸癌等的消化器官癌、肺癌、乳癌、前列腺癌及卵巢癌等。
圖1表示在相異濃度的Am80存在下將Panc-1以Am80懸浮培養1週,細胞數目變化之圖形。
圖2表示在懸浮培養條件下對Panc-1實施Am80處理,ALDH陽性細胞數的減少之圖形。
圖3表示在懸浮培養條件下對Panc-1實施Am80處理,CD24/CD44/ESA陽性細胞數的減少之圖形。
圖4表示在懸浮培養條件下並且在Am80存在下培養Panc-1,胰臟組織分化標記上昇之圖形。
圖5表示對MIA Paca2細胞實施Am80與蓓薩羅丁的共處理1週,細胞增殖活性的抑制之圖形。
圖6表示對MIA Paca2細胞實施Am80與5-aza-dC的共處理1週,細胞增殖活性的抑制之圖形。
圖7表示對MIA Paca2細胞實施Am80與SAHA的共處理1週,細胞增殖活性的抑制之圖形。
圖8表示對MIA Paca2細胞實施Am80與VPA的共處理1週,細胞增殖活性的抑制之圖形。
圖9表示Am80對人類胰臟癌細胞的細胞遊走能力產生的影響之顯微鏡照片。
圖10表示Am80對人類胰臟癌細胞的癌轉移抑制效果之圖形。
圖11表示Am80對人類胰臟癌細胞的致腫瘤抑制效果之圖形。
圖12表示對移值到無毛小鼠的人類胰臟癌幹細胞投予Am80的抑制效果之圖形。
圖13表示Am80對人類胰臟癌細胞的致腫瘤抑制效果之病理標本照片。
圖14表示Am80與抗癌劑.吉西他賓對人類胰臟癌細胞在體外的併用效果之圖形。
圖15表示Am80與抗癌劑.吉西他賓對人類胰臟癌細胞/無毛小鼠在體內的併用效果之圖形。
圖16表示Am80與表觀遺傳阻礙劑VPA對人類胰臟癌細胞/無毛小鼠在體內的併用效果之圖形。
圖17表示Am80與5-AZ對人類白血病細胞Kasumi-1的併用效果之等效線圖。
圖18表示對MCF-7細胞實施Am80與5-AZ的共處理96小時,細胞增殖活性的抑制之圖形。
圖19表示對LNCaP細胞實施Am80與5-AZ的共處理96小時,細胞增殖活性的抑制之圖形。
以下針對本發明的實施形態具體說明。
本發明的癌幹細胞之增殖抑制劑是以類視色素促效劑作為有效成分。在本發明中,類視色素促效劑包括其藥劑學上可容許的有機或無機的酸加成鹽。特別合適的類視色素促效劑可列舉他米巴羅汀(Am80)。
另外,本發明的癌幹細胞之增殖抑制劑適合與類視色素合成物促效劑併用。類視色素合成物促效劑還包括其藥劑學上可容許的有機或無機的酸加成鹽,特別合適者可列舉蓓薩羅丁(Targretin)。
本發明的癌幹細胞之增殖抑制劑,藉由併用
各種抗癌劑,而具有增強抗癌劑的抗癌活性的作用。
在本發明中,作為抗癌劑的DNA交互作用劑可列舉烷基化劑之環磷醯胺(cyclophosphamide)、美法崙(melphalan)、順鉑(Cisplatin)、卡鉑(Carboplatin)等,另外還可列舉DNA拓樸異構酶I阻礙劑的喜樹鹼(Camptothecin)、DNA拓樸異構酶II阻礙劑的依托泊苷(Etoposide)、道諾黴素(Daunorubicin)、阿黴素(doxorubicin)等。合適者可列舉可口服投予環磷醯胺、美法崙、順鉑、喜樹鹼、阿黴素。
作為抗癌劑的代謝拮抗劑,可列舉葉酸拮抗劑例如甲氨蝶呤(Methotrexate)及三甲氨蝶呤(Trimethotrexate)、嘧啶拮抗劑例如5-氟尿嘧啶、5-aza-dC、氮雜胞苷、阿糖胞苷(Cytarabine)及吉西他濱(Gemcitabine)、嘌呤拮抗劑例如氟達拉濱(Fludarabine)。合適者可列舉可口服投予甲氨蝶呤、5-氟尿嘧啶、5-aza-dC、氮雜胞苷、阿糖胞苷、吉西他濱、氟達拉濱。
作為抗癌劑的微管蛋白阻礙劑,合適者可列舉太平洋紫杉醇(Paclitaxel)、歐洲紫杉醇(Docetaxel)。
作為抗癌劑的分子標的治療劑,可列舉環氧合酶2阻礙劑的塞來昔布(Celecoxib)、羅非昔布(rofecoxib)、增殖因子訊號阻礙劑的厄洛替尼(Erlotinib)、伊馬替尼(imatinib)等。合適者可列舉可口服投予吉非替尼(Gefitinib)、伊馬替尼。
作為抗癌劑的表觀遺傳作用阻礙劑,可列舉
DNA甲基化阻礙劑之氮雜胞苷、組蛋白去乙醯酶阻礙劑的丙戊酸、SAHA(Vorinostat)、Romidepsin(FK228)。合適者可列舉可口服投予氮雜胞苷、丙戊酸、SAHA(Vorinostat)。
作為抗癌劑的荷爾蒙劑,可列舉醋酸亮丙瑞林(Leuprolide Acetate)、醋酸戈舍瑞林(Goserelin Acetate)、抗雌激素劑的泰莫西芬(Tamoxifen)、抗雄激素劑的氟他胺(flutamide)、比卡魯胺(Bicalutamide)、恩雜魯胺(Enzalutamide)等。合適者可列舉可口服投予泰莫西芬、氟他胺、比卡魯胺、恩雜魯胺。
抗癌劑的組合可列舉例如太平洋紫杉醇(或歐洲紫杉醇)與順鉑與TS-1的組合,歐洲紫杉醇與草酸鉑的組合,歐洲紫杉醇與分子標的藥的組合等,然而並不受該等所限定。
本發明的癌幹細胞之增殖抑制劑,可藉由將有效量以口服,經直腸、局部、或非口服、靜脈內或腫瘤內的注射之任一方式來投予,有效地阻礙人類的癌幹細胞及癌塊的成長。
本發明的癌幹細胞之增殖抑制劑可為錠劑、膠囊、丸劑、核糖體等的固態或膠體狀、或可為液狀(參考Cancer Chemotherapy Handbook version 2,15-34(1994))。
藉由本發明的癌幹細胞之增殖抑制劑進行治療時,可依照所治療的癌症的類型設定在任何適當的量,適用有效量的方法會隨著所治療的癌幹細胞的存在比例而
變。其中一個例子可設定在含有類視色素促效劑與類視色素合成物促效劑合計0.5~500mg/人類個體,且含有抗癌劑1.0~1000mg/人類個體。另外,類視色素促效劑適合定為0.5~20mg/人類個體。
本發明的癌幹細胞之增殖抑制劑,宜單獨使用類視色素促效劑,或與類視色素合成物促效劑併用,同時投予抗癌劑,使癌幹細胞分化,導致細胞凋亡,抑制癌細胞增殖或使其縮小。為了抑制癌幹細胞的增殖,可因應必要投予2週~2年。
以下基於實施例對本發明作說明。此外,下述實施例為例示,理所當然不會限定本發明。
<Am80對人類胰臟癌細胞球體的增殖抑制效果>
若使用人類胰臟癌細胞株,以在DMEM/F12中添加B27、20ng/mL EGF、20ng/mL bFGF、及4μg/mL heparin的培養基,使用低貼附性培養皿進行培養,則會形成細胞塊,能夠以懸浮狀態來進行培養,在幾個癌幹細胞標記與其他癌症文獻所報告的標記增加的狀態下進行培養。首先,將此含有癌幹細胞標記陽性細胞的細胞塊以添加Am80的培養基培養1週,解析對於細胞塊的增殖或癌幹細胞標記的表現量的影響。結果顯示,依存於他米巴羅汀
(Am80)的濃度,細胞塊的增殖會受到抑制。細胞塊的數量減少,細胞數也依存於濃度而減少(圖1)。若進一步將此細胞塊以含有Am80的培養基培養合計2週,則細胞塊進一步變小,細胞數減少。由以上的結果,判明了Am80具有抑制含有胰臟癌幹細胞的細胞集團增殖的作用。
<Am80對人類胰臟癌細胞Panc-1球體的ALDH活性的抑制效果>
如實施例1所示般,Am80會抑制胰臟癌細胞株的懸浮培養狀態下的細胞塊形成,因此認為其根源的癌幹細胞有減少的可能性。已知造血幹細胞或前驅細胞等的醛去氫酶(ALDH)活性高、分化細胞的活性低。於是在添加Am80並且懸浮培養1週的胰臟癌細胞中加入前驅物Bodipy-aminoacetaldehyde(ALDEFLUOR,Stem Cell Technologies),以流式細胞儀定量解析醛去氫酶活性代謝產生的Bodipy-aminoacetate的螢光陽性細胞數量。結果發現,若添加Am80進行培養,則ALDH活性依存於濃度而降低,表示癌幹細胞量有減少的可能性(圖2)。
<Am80對存在於人類胰臟癌細胞Panc-1球體的CD24+/CD44+/ESA+細胞的抑制效果>
使用將各種癌幹細胞表面標記的表現以蛋白質層級作
螢光標識的1次抗體,以流式細胞儀對於添加Am80並且懸浮培養1週的胰臟癌細胞進行解析,結果觀察到尤其是CD24+/CD44+/ESA+陽性細胞的存在率會因為添加Am80而明顯減少。尤其在10μM的Am80存在下,CD24+/CD44+/ESA+陽性細胞的存在率減半。亦即表示Am80有使癌幹細胞減少的可能性(圖3)。
<對人類胰臟癌細胞球體的分化標記增強效果>
接下來,由添加Am80懸浮培養1週的胰臟癌細胞萃取total RNA,以胰臟組織特異的分化標記所對應的引子進行定量RT-PCR,結果觀察到Pdx1或升糖素等的基因表現依存於Am80的濃度而上昇的情形。此結果表示Am80有促進含有癌幹細胞的細胞集團的分化的可能性(圖4)。
<併用Am80與蓓薩羅丁(bexarotene)對人類胰臟癌細胞MIA-Paca2球體的細胞增殖活性的影響>
將含有癌幹細胞標記陽性細胞的MIA-Paca2細胞塊以添加Am80(10nM-1μM)與蓓薩羅丁的培養基懸浮培養1週後,添加MTT試藥(Cell Counting Kit-8,Dojindo)進一步培養3小時,然後測定450nm的吸光度(OD450),解析對細胞塊的細胞增殖活性的影響。結果顯示,依存於Am80與蓓薩羅丁的濃度,細胞塊的細胞增殖活性緩慢受到抑制
(圖5)。
<併用Am80與DNA甲基阻礙劑.5-aza-dC對人類胰臟癌細胞MIA-Paca2球體的增殖活性的影響>
將含有癌幹細胞標記陽性細胞的MIA-Paca2細胞塊以添加Am80(10nM-1μM)與5-aza-dC的培養基懸浮培養1週後,添加MTT試藥(Cell Counting Kit-8,Dojindo)進一步培養3小時,然後測定450nm的吸光度,解析對細胞塊的細胞增殖的影響。結果顯示,依存於Am80與5-aza-dC的濃度,細胞塊的細胞增殖活性會受到抑制(圖6)。
<併用Am80與組蛋白去乙醯酶阻礙劑.SAHA對人類胰臟癌細胞MIA-Paca2球體的增殖抑制的影響>
將含有癌幹細胞標記陽性細胞的MIA-Paca2細胞塊以添加Am80(10nM-1μM)與SAHA的培養基懸浮培養1週後,添加MTT試藥(Cell Counting Kit-8,Dojindo)進一步培養3小時,然後測定450nm的吸光度,解析對細胞塊的細胞增殖活性的影響。結果顯示,依存於Am80與SAHA的濃度,細胞塊的細胞增殖活性會緩慢受到抑制(圖7)。
<併用Am80與組蛋白去乙醯酶阻礙劑.丙戊酸(VPA)對人類胰臟癌細胞MIA-Paca2球體的增殖抑制的影響>
將含有癌幹細胞標記陽性細胞的MIA-Paca2細胞塊以添加Am80(6.3nM~100nM)與VPA的培養基懸浮培養1週後,添加MTT試藥(Cell Counting Kit-8,Dojindo)進一步培養3小時,然後以450nm的吸光度來測定對細胞塊的細胞增殖的影響。結果顯示,Am80與VPA表現出相乘的細胞塊的細胞增殖阻礙活性(圖8)。
<Am80對人類胰臟癌幹細胞的細胞遊走能力的影響>
將含有胰臟癌幹細胞的胰臟癌細胞以抗體磁珠分離成CD133陽性細胞與陰性細胞後,添加1μM的Am80,在博登量測器(Boyden chamber)進行培養,觀察遊走至膜裏側的細胞。結果顯示,在CD133陽性細胞的癌幹細胞的部份,Am80顯著抑制細胞遊走能力(圖9)。
<Am80對人類胰臟癌細胞的癌轉移抑制效果>
將含有胰臟癌幹細胞的胰臟癌細胞(1×106個)移植至無毛小鼠的胰臟,測定一個月後轉移至肝臟所形成的腫瘤大小(Tumor volume)。Am80是以3mg/kg.day投予一個月。此結果與對照群相比,較能夠抑制胰臟癌的轉移(圖10)。
<Am80對人類胰臟癌細胞的致腫瘤抑制效果>
將含有胰臟癌幹細胞的胰臟癌細胞(1×106個)移植到無毛小鼠的皮下,2週後,對於觀察到形成腫瘤的小鼠以3mg/kg.day投予Am80一個月(Days after Am80 treatment)。結果顯示,並未觀察到對體重(Body weight)產生影響(A),然而與對照群相比,較能夠抑制體內胰臟癌的增殖(B)(圖11)。
<Am80對移植到無毛小鼠的人類胰臟癌幹細胞的抑制效果>
將含有胰臟癌幹細胞的胰臟癌細胞(1×106個)移植到無毛小鼠的皮下,2週後,對於觀察到形成腫瘤的小鼠以3mg/kg.day投予Am80一個月。然後將腫瘤取出,以胰蛋白酶處理,使用抗CD133抗體,以流式細胞儀測定胰臟癌幹細胞的比例,結果可知,Am80與對照群相比,較具有抑制體內胰臟癌幹細胞的作用(圖12)。
<Am80對人類胰臟癌細胞的致腫瘤抑制效果>
將含有胰臟癌幹細胞的胰臟癌細胞(1×106個)移植至無毛小鼠的皮下,2週後,對於觀察到形成腫瘤的小鼠以
3mg/kg.day投予Am80一個月。製作出各腫瘤的病理標本,並嘗試評估細胞組織形態,結果可知,與未投予Am80的對照群相比,胰臟癌組織的形態呈現分化型(圖13)。
<併用抗癌劑.吉西他賓與Am80對人類胰臟癌細胞的效果>
將人類胰臟癌細胞在懸浮培養狀態下加入吉西他賓(10nM),培養1週之後,進一步添加Am80,懸浮培養1週,計算細胞塊的數目(Number of colonies formed)。結果可知,對於抗癌劑處理後的胰臟癌細胞,Am80在體外也具有球體形成抑制效果(圖14)。
<併用抗癌劑.吉西他賓與Am80對人類胰臟癌細胞的效果>
將含有胰臟癌幹細胞的胰臟癌細胞(1×106個)移植到無毛小鼠的皮下,2週後,對於觀察到形成腫瘤的小鼠以3mg/kg.day每天投予Am80,以50mg/kg每隔3天投予吉西他賓一個月(Days after Am80 and Gem treatment)。結果可知,與對照群(未投予Am80及吉西他賓)或單獨投予吉西他賓相比,同時投予Am80與吉西他賓較顯著抑制體內胰臟癌的增殖(圖15)。此處Gem表示吉西他賓。
<併用表觀遺傳阻礙劑VPA與Am80對人類胰臟癌細胞的效果>
將含有胰臟癌幹細胞的胰臟癌細胞(1×106個)移植到無毛小鼠的皮下,2週後,對於觀察到形成腫瘤的小鼠以3mg/kg.day每天投予Am80,以500mg/kg每隔3天投予VPA,投予一個月(Days after Am80 and VPA treatment)。結果可知,與對照群(未投予Am80及VPA)或單獨投予VPA、單獨投予Am80相比,同時投予Am80與VPA較顯著抑制體內胰臟癌的增殖(圖16)。
<併用Am80與Docetaxel(DXL)對人類胰臟癌細胞MIA-Paca2/無毛小鼠的增殖抑制的影響>
使用套管針將含有癌幹細胞標記陽性細胞的人類胰臟癌細胞MIA-Paca2的腫瘤片移植至6週齡的雌性BALB/cAJcl-nu無毛小鼠(4隻/群,只有對照群是5隻)的背側部皮下。從腫瘤體積達到100~200mm3的時間點開始投予。Am80是以2mg/kg投予1次/天,連日口服投予21天,DXL是以5mg/kg投予至靜脈內,從第1天開始每隔4天投予3次。併用群是以與各單劑相同用量、投予法來投予,在投予結束翌日(第22天)測定腫瘤徑。將腫瘤的長徑及短徑的測定值代入長徑×短徑2/2的式子求得腫瘤
體積(mm3)。此外,對照群是將生理食鹽水投予至腹腔內,從第1天開始每隔4天投予3次。結果顯示,Am80與DXL的併用效果高於各單劑效果,而且表現出相乘的細胞增殖阻礙活性。將結果揭示於下述表1。
<併用Am80與DNA甲基化阻礙劑.氮雜胞苷(5-AZ)對人類白血病細胞株Kasumi-1的增殖抑制的影響>
將含有癌幹細胞標記陽性細胞的人類白血病細胞株Kasumi-1以添加20%FBS的RPMI1640培養基進行培養,使用等效線圖(Isobrogram),檢討Am80與5-AZ的併用所產生的增殖抑制作用。其IC50值分別為1.0μM、8.4μM。將這些濃度定為1.0時,求得併用效果的比率,在將兩軸的1.0連結而成的直線上的情況,表現出相加效果,在直線下側的情況,表現出相乘效果。Am80與5-AZ的併用,在增殖抑制作用之中,表現出相乘效果(圖17)。
<併用Am80與DNA甲基化阻礙劑.5-AZ對人類乳癌細胞株MCF-7的增殖抑制的影響>
將含有癌幹細胞標記陽性細胞的人類乳癌細胞株MCF-7以添加2%FBS的RPMI1640培養基進行培養,檢討Am80與5-AZ的併用所產生的增殖抑制作用。暴露96小時的IC50值分別為1μM、20μM,因此Am80是檢討公比為2且濃度範圍為0.125μM至1μM的增殖抑制作用,另外5-AZ是檢討公比為2且濃度範圍為2.5μM至20μM的增殖抑制作用。在併用的情形,使用這些濃度來檢討增殖抑制作用。Am80與5-AZ的併用,在增殖抑制作用之中,表現出相乘效果(圖18)。
<併用Am80與Docetaxel(DXL)對人類乳癌細胞株MCF-7/無毛小鼠的增殖抑制的影響>
使用套管針將含有癌幹細胞標記陽性細胞的人類乳癌細胞株MCF-7的腫瘤片移植至6週齡的雌性BALB/cAJcl-nu無毛小鼠(5隻/群)的背側部皮下。從腫瘤體積達到100-200mm3的時間點開始投予。Am80是以1mg/kg投予1次/天,連日口服投予21天,DXL是以3.5mg/kg投予至靜脈內,從第1天開始每隔4天投予3次。併用群是以與各單劑相同的用量、投予法來投予,在投予結束翌日(第22天)
測定腫瘤徑。使用測徑器測定腫瘤的長徑及短徑,代入長徑×短徑2/2的式子求得腫瘤體積(mm3)。此外,對照群是將生理食鹽水投予至腹腔內,從第1天開始每隔4天投予3次。結果顯示,對於增殖緩慢的人類乳癌細胞株MCF-7,Am80與DXL的併用效果高於各單劑的效果,而且表現出相乘的細胞增殖阻礙活性。將結果揭示於下述表2。
<併用Am80與DNA甲基化阻礙劑.5-AZ對人類前列腺癌細胞株LNCaP的增殖抑制的影響>
將含有癌幹細胞標記陽性細胞的人類前列腺癌細胞株LNCaP以添加10%FBS的RPMI1640培養基進行培養,檢討Am80與5-AZ的併用所產生的增殖抑制作用。暴露96小時的IC50值分別為2μM、25μM,因此Am80是檢討公比為2且濃度範圍為0.125μM至1μM的增殖抑制作用,另外,5-AZ是檢討公比為2且濃度範圍為1.56μM至
12.5μM的增殖抑制作用。在併用的情況,使用這些濃度來檢討增殖抑制作用。Am80與5-AZ的併用,在增殖抑制作用之中,表現出相乘效果(圖19)。
<併用Am80與Docetaxel(DXL)對人類前列腺癌細胞株LNCaP/無毛小鼠的增殖抑制的影響>
使用套管針將含有癌幹細胞標記陽性細胞的人類前列腺癌細胞株LNCaP的腫瘤片移植至6週齡的雌性BALB/cAJcl-nu無毛小鼠(4隻/群)的背側部皮下。從腫瘤體積達到100-200mm3的時間點開始投予。Am80是以1mg/kg投予1次/天,連日口服投予21天,DXL是以5mg/kg投予至靜脈內,從第1天開始每隔4天投予3次。併用群是以與各單劑相同用量、投予法來投予,在投予結束翌日(第22天)測定腫瘤徑。使用測徑器測定腫瘤的長徑及短徑,代入長徑×短徑2/2的式子求得腫瘤體積(mm3)。此外,對照群是將生理食鹽水投予至腹腔內,從第1天開始每隔4天投予3次。結果顯示,對於人類前列腺癌細胞株LNCaP,Am80與DXL的併用效果高於各單劑的效果,而且表現出相乘的細胞增殖阻礙活性。將結果揭示於下述表3。
若使用類視色素促效劑.他米巴羅汀(Am-80)單劑或與類視色素合成物促效劑.蓓薩羅丁(Targretin)兩劑併用,則會抑制人類胰臟癌幹細胞的標記表現及增殖,另外,藉由併用各種抗癌劑,可觀察到增強抗癌劑的效果。此外,對於各種癌症,藉由併用Am80與各種抗癌劑,可觀察到增強抗癌劑的效果。
Claims (7)
- 一種癌幹細胞之增殖抑制劑,其係以類視色素促效劑作為有效成分。
- 如申請專利範圍第1項之癌幹細胞之增殖抑制劑,其中前述類視色素促效劑為他米巴羅汀(Am-80)。
- 如申請專利範圍第1或2項之癌幹細胞之增殖抑制劑,其中進一步以類視色素合成物(rexinoid)促效劑作為有效成分。
- 如申請專利範圍第3項之癌幹細胞之增殖抑制劑,其中前述類視色素合成物促效劑為蓓薩羅丁。
- 如申請專利範圍第1或2項之癌幹細胞之增殖抑制劑,其中含有抗癌劑。
- 如申請專利範圍第5項之癌幹細胞之增殖抑制劑,其中含有類視色素促效劑0.5~20mg/人類個體,含有類視色素促效劑與類視色素合成物促效劑合計0.5~500mg/人類個體,且含有抗癌劑1.0~1000mg/人類個體。
- 如申請專利範圍第5項之癌幹細胞之增殖抑制劑,其中前述抗癌劑係選自DNA交互作用劑、代謝拮抗劑、微管蛋白交互作用劑、分子標的治療劑、表觀遺傳之作用阻礙劑及荷爾蒙劑所構成之群組。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014105543 | 2014-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201607531A true TW201607531A (zh) | 2016-03-01 |
Family
ID=54554092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104116251A TW201607531A (zh) | 2014-05-21 | 2015-05-21 | 癌幹細胞之增殖抑制劑 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20170079942A1 (zh) |
EP (1) | EP3146978B1 (zh) |
JP (1) | JPWO2015178426A1 (zh) |
KR (1) | KR20170005069A (zh) |
CN (2) | CN114392252A (zh) |
AU (1) | AU2015262349A1 (zh) |
CA (1) | CA2949640A1 (zh) |
ES (1) | ES2928499T3 (zh) |
MX (1) | MX2016015092A (zh) |
RU (1) | RU2016150116A (zh) |
TW (1) | TW201607531A (zh) |
WO (1) | WO2015178426A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2906800A1 (en) | 2013-03-15 | 2014-09-18 | Avisenna Cosmetics, Llc | Topical compositions for reducing the effects of aging |
WO2018117196A1 (ja) * | 2016-12-20 | 2018-06-28 | 大日本住友製薬株式会社 | がん幹細胞を標的とする医薬 |
IT201800005072A1 (it) * | 2018-05-04 | 2019-11-04 | Nuovi farmaci prosenescenza | |
RU2702910C2 (ru) * | 2018-12-20 | 2019-10-14 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения количества стволовых клеток рака молочной железы |
RU2700695C2 (ru) * | 2019-02-27 | 2019-09-19 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения клоногенной активности стволовых клеток рака молочной железы |
WO2021261601A1 (ja) * | 2020-06-26 | 2021-12-30 | ラクオリア創薬株式会社 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
AU2022206438A1 (en) * | 2021-01-08 | 2023-07-20 | Syros Pharmaceuticals, Inc. | Treatment regimens with fixed doses of tamibarotene |
CN114045259B (zh) * | 2021-11-08 | 2024-04-05 | 山东第一医科大学(山东省医学科学院) | 一种抑制肿瘤干细胞的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009504774A (ja) * | 2005-08-18 | 2009-02-05 | メルク エンド カムパニー インコーポレーテッド | 癌を治療するためにsaha及びターグレチンの併用方法 |
EP2005954B8 (en) * | 2006-03-23 | 2012-11-28 | TMRC Co., Ltd. | Kit for cancer therapy and pharmaceutical composition for cancer therapy |
-
2015
- 2015-05-20 AU AU2015262349A patent/AU2015262349A1/en not_active Abandoned
- 2015-05-20 ES ES15796913T patent/ES2928499T3/es active Active
- 2015-05-20 MX MX2016015092A patent/MX2016015092A/es unknown
- 2015-05-20 EP EP15796913.0A patent/EP3146978B1/en active Active
- 2015-05-20 JP JP2016521132A patent/JPWO2015178426A1/ja active Pending
- 2015-05-20 KR KR1020167034364A patent/KR20170005069A/ko unknown
- 2015-05-20 CN CN202210166733.7A patent/CN114392252A/zh active Pending
- 2015-05-20 CN CN201580025982.2A patent/CN106456770A/zh active Pending
- 2015-05-20 US US15/312,484 patent/US20170079942A1/en not_active Abandoned
- 2015-05-20 CA CA2949640A patent/CA2949640A1/en not_active Abandoned
- 2015-05-20 WO PCT/JP2015/064523 patent/WO2015178426A1/ja active Application Filing
- 2015-05-20 RU RU2016150116A patent/RU2016150116A/ru not_active Application Discontinuation
- 2015-05-21 TW TW104116251A patent/TW201607531A/zh unknown
-
2019
- 2019-11-04 US US16/672,783 patent/US20200061007A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2928499T3 (es) | 2022-11-18 |
MX2016015092A (es) | 2017-05-09 |
AU2015262349A1 (en) | 2017-02-02 |
EP3146978A4 (en) | 2017-12-20 |
KR20170005069A (ko) | 2017-01-11 |
RU2016150116A3 (zh) | 2018-09-25 |
RU2016150116A (ru) | 2018-06-22 |
US20170079942A1 (en) | 2017-03-23 |
US20200061007A1 (en) | 2020-02-27 |
EP3146978A1 (en) | 2017-03-29 |
CA2949640A1 (en) | 2015-11-26 |
CN114392252A (zh) | 2022-04-26 |
WO2015178426A1 (ja) | 2015-11-26 |
EP3146978B1 (en) | 2022-07-20 |
JPWO2015178426A1 (ja) | 2017-04-20 |
CN106456770A (zh) | 2017-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201607531A (zh) | 癌幹細胞之增殖抑制劑 | |
Baharuddin et al. | Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines | |
Mirzaei et al. | The role of microRNA-338-3p in cancer: growth, invasion, chemoresistance, and mediators | |
Mao et al. | Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib | |
ES2409755T3 (es) | Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado | |
Han et al. | Piperine (PP) enhanced mitomycin-C (MMC) therapy of human cervical cancer through suppressing Bcl-2 signaling pathway via inactivating STAT3/NF-κB | |
Zhuang et al. | Pien Tze Huang inhibits tumor cell proliferation and promotes apoptosis via suppressing the STAT3 pathway in a colorectal cancer mouse model | |
KR20170084034A (ko) | 암 치료용 의약 조성물 제조에서의 아젤니디핀의 용도 | |
US9801844B2 (en) | Methods and compositions for the treatment of cancer | |
Guo et al. | Salvianolic acid B reverses multidrug resistance in nude mice bearing human colon cancer stem cells | |
Zhang et al. | miR-634 exhibits anti-tumor activities toward hepatocellular carcinoma via Rab1A and DHX33 | |
Huang et al. | Studies on the anti‑angiogenic effect of Marsdenia tenacissima extract in vitro and in vivo | |
Wei et al. | Scutellaria barbata D. Don induces G1/S arrest via modulation of p53 and Akt pathways in human colon carcinoma cells | |
Li et al. | Inhibition of Stat3 signaling pathway by natural product pectolinarigenin attenuates breast cancer metastasis | |
Zhao et al. | Raltitrexed inhibits HepG2 cell proliferation via G0/G1 cell cycle arrest | |
JP2019500334A (ja) | がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター4(mct4)アンチセンスオリゴヌクレオチド(aso)阻害剤 | |
Zhang et al. | Cryptotanshinone targets tumor-initiating cells through down-regulation of stemness genes expression | |
Wu et al. | HuaChanSu suppresses tumor growth and interferes with glucose metabolism in hepatocellular carcinoma cells by restraining Hexokinase-2 | |
JP7349983B2 (ja) | 障害治療用のトリプトニドまたはトリプトニド含有組成物 | |
CN108026104A (zh) | 利用低分子化合物的癌及纤维化的抑制和再生促进的效果 | |
Zhu et al. | NFκB and TNFα as individual key molecules associated with the cisplatin-resistance and radioresistance of lung cancer | |
Jiang et al. | Combination treatment of gemcitabine and sorafenib exerts a synergistic inhibitory effect on non‑small cell lung cancer in vitro and in vivo via the epithelial‑to‑mesenchymal transition process | |
Huang et al. | Evidence that high-migration drug-surviving MOLT4 leukemia cells exhibit cancer stem cell-like properties | |
CN105106196A (zh) | 阿可拉定在制备用于抑制肝癌干细胞药物中的用途 | |
Li et al. | The Active Fraction of Polyrhachis vicina Roger (AFPR) activates ERK to cause necroptosis in colorectal cancer |